The Democratic Republic of Congo's ongoing Ebola outbreak has taken a pivotal turn as the first patients receive experimental treatments in a critical trial that could hold the key to reducing the high mortality rate associated with the deadly virus. Just six weeks after the World Health Organization (WHO) declared the current crisis a public health emergency of international concern on 17 May 2026, scientists and medical teams are pinning their hopes on the Partners trial, which is evaluating two promising drugs against the Bundibugyo strain.
The trial involves randomly assigning patients to receive either remdesivir, an antiviral developed by Gilead Sciences, or MBP134, a monoclonal antibody from Mapp Biopharmaceutical. Remdesivir is administered as a 10-day intravenous therapy, while MBP134 is given as a single intravenous infusion. The trial's focus on the Bundibugyo strain is crucial, given that it still claims the lives of approximately one in three infected individuals despite generally having a lower fatality rate than the more common Zaire strain.
The need for effective treatments is pressing, with 1,792 confirmed cases and 625 deaths reported as of 9 July 2026. The WHO reports that the outbreak remains in an “expansion phase,” highlighting the ongoing challenge facing medical teams on the ground. Researchers are closely monitoring death rates across the different treatment groups to determine if the experimental drugs can significantly improve patient outcomes.
Despite the rapid progress made in launching the trial, the wider public health response in the DRC faces significant obstacles. Efforts to identify cases, isolate infected individuals, and trace contacts are hampered by low public trust in authorities, a highly mobile population, and recent protests by frontline workers over unpaid wages. The closure of Bunia airport is reportedly impeding the delivery of essential supplies, including banknotes for staff payments.
The introduction of potentially life-saving drugs through the Partners trial offers a critical new tool in the fight against Ebola. With about 75% of known contacts currently being traced, any statistically significant reduction in mortality rates would represent a major breakthrough, providing medical teams with a vital intervention beyond basic supportive care. The success of this trial is of particular concern to British readers, given that the UK has invested heavily in global health security and is working closely with international partners to combat infectious diseases.